Investigating the role of GPR3 in Alzheimer's disease
Cell-type-specific functions of GPR3 in Alzheimer’s disease
This study is looking at how a specific protein called GPR3 affects the buildup of harmful substances in the brain and inflammation in people with Alzheimer's disease, using a special mouse model to find new ways to improve memory and thinking skills for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10983771 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific receptor, GPR3, influences the progression of Alzheimer's disease (AD) by examining its effects on the accumulation of amyloid-beta (Aβ) and the brain's inflammatory response. The study utilizes a unique mouse model that allows researchers to observe the differences in cognitive functions and Aβ levels when GPR3 signaling is altered. By exploring the cell-type-specific mechanisms involved in neuroinflammation, the research aims to uncover new therapeutic targets that could lead to better treatments for AD. Patients may benefit from insights gained about how to modulate GPR3 activity to improve cognitive health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent cognitive decline in Alzheimer's disease patients.
How similar studies have performed: Previous research has shown promising results in targeting G protein-coupled receptors for therapeutic benefits in other conditions, suggesting potential for success in this novel approach for Alzheimer's disease.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Thathiah, Amantha — University of Pittsburgh at Pittsburgh
- Study coordinator: Thathiah, Amantha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.